Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Baseline T-cell fitness and subtype-specific CD19 loss as drivers of blinatumomab resistance in B-ALL

View Full Paper
Ask AI
Bookmark
Share

Authors

SBSonja BendigALAnna LaquaMSMonika Szczepanowski

Discussion

Loading...

Member takes

Overview

Analysis reveals T-cell exhaustion and gene expression signatures predicting blinatumomab resistance in B-ALL.

Key Points

  • B-cell aplasia patients showed distinctive T-cell profiles, with notable differences in baseline fitness.
  • CD4+ T cell percentages were significantly higher in patients clearing B cells post-blinatumomab treatment.
  • Using scRNA sequencing, unique gene expression signatures were identified for T cells in both response groups.
  • Understanding T-cell dynamics under blinatumomab could enhance predictive models for B-ALL treatment success.

Cite This Study

Bendig et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5e8https://doi.org/10.1182/blood-2025-32
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Blinatumomab demonstrates MRD eradication in MRD-positive/chemotherapy-delayed pediatric B-ALL and high response in relapsed/refractory cases: a multicenter cohort study2025
  2. 2Blinatumomab efficacy differs between newly diagnosed and relapsed/refractory B-ALL: Impact on MRD clearance and survival2025
  3. 3Short-term blinatumomab regimen in newly diagnosed induction and MRD-negative consolidation treatment of B-cell acute lymphoblastic leukemia2025
  4. 4Low-intensity cytoreduction with low-dose cytarabine prior to blinatumomab for pediatric and AYA R/R ALL integrated with multi-omics analysis to discover predictive biomarkers: Initial results from JPLSG-ALL-R19-blin2025
  5. 5T-cell engaging bispecific antibody shows potent MRD negativity with variable remission and survival outcomes: A bayesian meta-analysis of randomized controlled trials2025